Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. (SRPT): 25 pipeline candidates · 7 upcoming catalysts · ~17 mo cash runway · 25 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
17.0 months
D/E 1.11 · 15% dilution
Lead: Approved
25 candidates
7 upcoming, next in ~135d
0 buys · 1 sell (180d)
A transparent, data-derived signal for Sarepta Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.8B
Cash
$477.6M
Quarterly Burn
$202.7M
Runway
17.0 mo
Revenue
$730.8M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (25 candidates)
| Drug | Phase |
|---|---|
| amondys 45 | Approved |
| amondys 45 | Approved |
| antibiotics | Phase 4 |
| aro-dm1 | Preclinical |
| casimersen | Phase 3 |
| delandistrogene moxeparvovec | Phase 3 |
| elevidys | Phase 4 |
| eteplirsen | Phase 3 |
| exondys 51 | Approved |
| exondys 51 | Approved |
Showing 10 of 25 candidates. Sign up for full pipeline.
Upcoming Catalysts (7)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
341
Total value held
$2.38B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 14,755,277 | $321.1M |
| vanguard capital management llc | 9,156,470 | $199.2M |
| vanguard portfolio management llc | 6,640,692 | $144.5M |
| state street corp | 6,613,314 | $143.9M |
| aqr capital management llc | 6,433,112 | $138.6M |
| two sigma investments, lp | 4,593,195 | $99.9M |
| first trust advisors lp | 4,135,788 | $90.0M |
| ra capital management, l.p. | 3,902,596 | $84.9M |
| susquehanna international group, llp | 3,818,732 | $83.1M |
| morgan stanley | 2,596,993 | $56.5M |
Showing top 10 of 341 institutional holders of Sarepta Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Sarepta Therapeutics, Inc.'s pipeline?
Sarepta Therapeutics, Inc. (SRPT) has 25 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Sarepta Therapeutics, Inc.'s lead drug candidate?
Sarepta Therapeutics, Inc.'s most advanced tracked candidate is amondys 45 (Approved) for 1 INDICATIONS AND USAGE AMONDYS 45 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with AMONDYS 45 [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification of a clinical benefit in conf.
What is Sarepta Therapeutics, Inc.'s next catalyst?
Sarepta Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of High Dos" — expected October 31, 2026.
What is Sarepta Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Sarepta Therapeutics, Inc. has approximately 17.0 months of cash runway.
What is Sarepta Therapeutics, Inc.'s market capitalization?
Sarepta Therapeutics, Inc.'s market capitalization is approximately $1.8B.
Get the full picture on Sarepta Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.